Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week on the BowTiedBiotech podcast, we break down a packed slate of clinical, regulatory, and financing developments across the sector, led by AstraZeneca and Ionis’ surprising ATTR-CM failure and GSK and Hansoh’s potentially important survival win for a B7-H3 ADC in small cell lung cancer. We also discuss Roche’s decision to exit two Huntington’s disease programs, GSK’s termination of its Alector partnership, the FDA’s strong first-half approval pace, and the return of larger biotech transactions through Vertex’s acquisition of Crinetics. Rounding out the episode, we examine MeiraGTx’s royalty-backed financing, the growing regulatory threat facing Amgen’s Tavneos, and AstraZeneca’s latest China-sourced respiratory deal, with a focus on what the headlines leave out and where the real risks remain.
📣🎙️ TODAY’S PODCAST:
[02:01] AstraZeneca’s ATTR Clinical Failure
[04:48] Huntington’s Mechanistic Trap
[07:22] Billion-Dollar Deal Mirages
[09:31] Vertex Pays for Certainty
[10:51] MeiraGTx Mortgages Future Revenue
[13:25] FDA Approval Isn’t Safety
[14:08] Tavneos Faces Regulatory Crisis
[15:30] Ris-Rez Survival Test
[19:45] China Shifts Biotech Gravity
[20:52] Evidence Beats Biotech Narratives
Thanks for reading BowTiedBiotech! Please help us grow our audience - sharing is caring!
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
